Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Geron Corporation - Common Stock (NQ:GERN)

1.490 -0.040 (-2.61%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Geron Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron to Participate in the B. Riley Securities Virtual Oncology Conference
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron Announces IMerge Phase 3 Presentations at ASH Highlighting Significant Durability of Transfusion Independence and Breadth of Effect Across MDS Subgroups with Imetelstat in Lower Risk MDS
From Geron Corporation
Via Business Wire
Geron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis
From Geron Corporation
Via Business Wire
Geron Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS
From Geron Corporation
Via Business Wire
Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron to Participate at Upcoming Investor Conferences in November
From Geron Corporation
Via Business Wire
Geron IMerge Phase 3 Presentations at Upcoming ASH Annual Meeting Reinforce Significant Durability and Breadth of Effect of Imetelstat in Lower Risk MDS
From Geron Corporation
Via Business Wire
Geron Corporation Reports Business Highlights and Third Quarter 2023 Financial Results
From Geron Corporation
Via Business Wire
Geron to Announce Third Quarter 2023 Financial Results on November 2, 2023
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron Announces EMA Validation of Marketing Authorization Application for Imetelstat for the Treatment of Lower Risk MDS
From Geron Corporation
Via Business Wire
Geron Announces Appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer and Treasurer, and the Retirement of Olivia Bloom, Geron's Long-Time Chief Financial Officer
From Geron Corporation
Via Business Wire
Geron Announces Data Presentations from IMerge Phase 3 Evaluating Imetelstat in Lower Risk MDS at Society of Hematologic Oncology Annual Meeting
From Geron Corporation
Via Business Wire
Geron to Participate in the Baird 2023 Global Healthcare Conference
From Geron Corporation
Via Business Wire
Geron Announces PDUFA Date for Imetelstat NDA in Lower Risk MDS
From Geron Corporation
Via Business Wire
Geron Announces FDA Acceptance of New Drug Application for Imetelstat for the Treatment of Lower Risk MDS
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron Corporation Reports Business Highlights and Second Quarter 2023 Financial Results
From Geron Corporation
Via Business Wire
Geron to Announce Second Quarter 2023 Financial Results on August 3, 2023
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron Announces U.S. Expanded Access Protocol for Imetelstat in Lower Risk MDS
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron Announces Submission of New Drug Application to FDA for First-in-Class Telomerase Inhibitor Imetelstat
From Geron Corporation
Via Business Wire
Geron Announces First Patient Dosed in Investigator-Led Phase 2 IMpress Trial Evaluating Imetelstat in Patients with Relapsed/Refractory AML or Higher Risk MDS
From Geron Corporation
Via Business Wire
Geron Announces New Data and Analyses from IMerge Phase 3 Presented at EHA Reporting Robust Durability of Transfusion Independence, Evidence of Disease-Modifying Activity and Favorable Fatigue PRO in Imetelstat-Treated Lower Risk MDS Patients
From Geron Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback